A phase 2, multicentre, open-label, single arm study to evaluate the effectiveness and safety of rezafungin (as acetate) in the treatment of chronic pulmonary aspergillosis (CPA) in patients with limited treatment options.
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
MUNDIPHARMA RESEARCH LIMITED
Cita
A phase 2, multicentre, open-label, single arm study to evaluate the effectiveness and safety of rezafungin (as acetate) in the treatment of chronic pulmonary aspergillosis (CPA) in patients with limited treatment options. (MR907-2502). MUNDIPHARMA RESEARCH LIMITED. 2025IP:AMPARO SOLÉ JOVER.
Portal de investigación